Article

Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia

2022-12-03

Abstract excerpt

<h4>ABSTRACT</h4> The hypomethylating agent 5-azacytidine (AZA) is the first-line therapy for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Evidence suggests that the anti-tumor effect of AZA results partly from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) whose expression is induced by hypomethylation. Through a proteogenomic approach, we analyzed the impact of AZ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1e4f89f4-dbf6-537a-8d16-9062b9104607
DOI: 10.1101/2022.12.02.518683

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemiaDOI 10.1101/2022.12.02.518683Read

Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemiaSemantic proximity Read

Azacytidine restores T cell function in AML by modulating DNA methylationSemantic proximity Read

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteomeSemantic proximity Read

Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodelingSemantic proximity Read

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancersSemantic proximity Read

5-azacytosine induces cytotoxicity via 5-methylcytosine depletion on chromatin-associated RNA in leukemiaSemantic proximity Read

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity Read

mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid LeukemiaSemantic proximity Read

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the EpicenterSemantic proximity Read

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulationSemantic proximity Read

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.Semantic proximity Read